Anika Therapeutics, Inc. (ANIK)

NASDAQ: ANIK · USD

$21.4

+0.02 (+0.1%)· Recorded snapshot

Market cap	286M
Revenue (ttm)	120.7M
Net income (ttm)	-3.8M
EPS (ttm)	-$0.28
Shares out	13.4M
P/E (forward)	24.1x
Volume	82,309
Beta	0.21

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 120.7M
Net income (ttm): -3.8M
EPS (ttm): -$0.28
P/E (forward): 24.1x
Market cap: 286M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Trzymaj

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E24.1

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-2.2

P25 n/aP50 n/aP75 n/a

ROIC-2.1

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All ANIK indicators

Market & fundamental data

Available fields

242

Groups with data

Currency

USD

Showing 242 of 242 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0000898437
Company name	Anika Therapeutics, Inc.
Country	United States
Country code	US
CUSIP number	035255108
Earnings date	2026-11-06
Earnings time	bmo
Employees	235
Employees change	-53
Employees growth	-18.4%
Enterprise value	$272.8M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	1983
In index	RUSSELL2000
Industry	Drug Manufacturers - Specialty & Generic
IPO date	1993-04-29
Is primary listing	Yes
Is SPAC	No
ISIN number	US0352551081
Last 10-K release date	2026-03-03
Last earnings date	2026-07-29
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$286M
Market cap category	Micro-Cap
Next earnings date	2026-11-06
Options	Yes
Price	$21.37
Price currency	USD
Sector	Healthcare
SIC code	3841
Stock price date	2026-10-28
Symbol	ANIK
U.S. state	Massachusetts
Website	https://www.anika.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Adjusted P/E ratio	20.55x
Earnings yield	-1.3%
EV/EBITDA	90.61x
EV/FCF	490.13x
EV/Sales	2.28x
FCF / EV yield	0.2%
FCF yield	0.19%
Forward EV/Sales	2.25x
Forward P/E	24.09x
Forward P/S	2.35x
Industry forward P/E	13.87x
Industry P/E	173.94x
P/B ratio	2.08x
P/FCF ratio	513.55x
P/OCF ratio	48.29x
P/S ratio	2.39x
PEG ratio	2.4x
Price / tangible book value	2.26x
Price/EBITDA ratio	94.94x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	-2.15%
EBITDA margin	2.52%
FCF margin	0.47%
Gross margin	62.16%
Operating margin	-2.15%
Pretax margin	-2.41%
Profit margin	-3.14%
Profit per employee	$-16,102
Profitable quarters	1
Revenue per employee	$513,421
ROA	-0.87%
ROA (5Y)	-1.2%
ROCE	-1.61%
ROE	-2.19%
ROE (5Y)	-2.13%
ROIC	-2.14%
ROIC (5Y)	-3.57%
SBC / revenue	10.9%
Tax / revenue	0.17%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	1
EPS growth years	2
FCF growth 5Y	-39.38%
Gross profit growth	13.33%
Gross profit growth (Q)	47.91%
Gross profit growth 3Y	-9.72%
Gross profit growth 5Y	-3.48%
Net income growth quarters	1
Net income growth years	2
OCF growth	-4.81%
OCF growth 10Y	-15.24%
OCF growth 5Y	-10.34%
Revenue growth	5.33%
Revenue growth (Q)	15.56%
Revenue growth (QoQ)	10.12%
Revenue growth 10Y	1.55%
Revenue growth 3Y	-9.38%
Revenue growth 5Y	-2.48%
Revenue growth quarters	3
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-5.4M
Depreciation and amortization	$5.6M
EBIT	$-2.6M
EBITDA	$3M
EPS	$-0.28
FCF per share	$0.04
Financing cash flow	$-16.3M
Free cash flow	$562,000
Free cash flow minus SBC	$-12.6M
Gross profit	$75M
Income taxes	$208,000
Investing cash flow	$-4.1M
Net cash flow	$-14.8M
Net income	$-3.8M
Operating cash flow minus SBC	$-7.2M
Operating income	$-2.6M
Revenue	$120.7M
Stock-based compensation	$13.1M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	3.62
Book value per share	$10.26
Debt / EBITDA	8.31
Debt / equity	0.18
Debt / FCF	44.93
Goodwill	$7.8M
Long-term assets	$84.3M
Long-term liabilities	$24M
Net cash (debt)	$13.2M
Net cash / market cap	4.56%
Net cash growth	-53.29%
Net debt / EBITDA	-4.33
Net debt / equity	-0.1
Net debt / FCF	-23.42
Piotroski F-Score	4
Property, plant and equipment	$65.1M
Shareholders' equity	$137.3M
Tangible book value	$127.8M
Tangible book value per share	$9.55
Total assets	$183.5M
Total cash	$38.4M
Total debt	$25.3M
Total liabilities	$46.2M
WACC	4.97%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.65
Current assets	$99.2M
Current liabilities	$22.1M
Current ratio	4.48
Inventory turnover	2.01
Net working capital	$40.6M
Quick ratio	3.05
Working capital	$77M
Working capital turnover	1.51

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	4.23%
Dividend yield	0%
Shareholder yield	4.23%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	-51.5%
10Y return CAGR	-6.98%
10Y total return	-51.5%
150-day SMA	$17.38
15Y price change	244.12%
15Y return CAGR	8.59%
15Y total return	244.12%
1D price change	0.09%
1M price change	4.91%
1M total return	4.91%
1W price change	4.55%
1W total return	4.55%
1Y price change	120.31%
1Y return CAGR	120.43%
1Y total return	120.31%
20-day SMA	$20.27
200-day SMA	$15.96
20Y price change	61.41%
20Y return CAGR	2.42%
20Y total return	61.41%
3M price change	42.28%
3M total return	42.28%
3Y price change	15.33%
3Y return CAGR	4.87%
3Y total return	15.33%
50-day SMA	$20.66
50-day SMA vs 200-day SMA	50over200
52-week high	$22.88
52-week high date	2026-08-10
52-week low	$9.01
52-week low date	2026-01-28
5Y price change	-48.27%
5Y return CAGR	-12.35%
5Y total return	-48.27%
6M price change	34.83%
6M total return	34.83%
All-time high	$75.72
All-time high date	2019-10-25
All-time low	$0.69
All-time low date	2000-12-29
Average true range (ATR)	$0.73
Average volume	107.6K
Beta (1Y)	0.54
Beta (2Y)	0.97
Beta (5Y)	0.21
Change from 52-week high	-6.6%
Change from 52-week low	137.18%
Change from all-time high	-71.78%
Change from all-time low	3,008.36%
Change from open	-0.33%
Day's gap	0.42%
Dollar volume	$1.8M
High price	$21.49
Low price	$21.13
Monthly RSI	60.97
Open price	$21.44
Position in 52-week range	66.67%
Premarket change	-1.64%
Premarket close	$21.35
Premarket price	$21.00
Premarket volume	600
Previous close	$21.35
Price vs 150-day SMA	22.94%
Price vs 20-day SMA	5.44%
Price vs 200-day SMA	33.93%
Price vs 50-day SMA	3.46%
Relative volume	0.76
RSI	60.44
Sharpe ratio	1.77
Sharpe ratio (3Y)	0.27
Sharpe ratio (5Y)	-0.15
Sortino ratio	3.26
Sortino ratio (3Y)	0.47
Sortino ratio (5Y)	-0.08
Volume	82.3K
Weekly RSI	69.86
YTD price change	122.37%
YTD total return	122.37%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	11.3M
Float percentage	84.33%
Shares change (QoQ)	1.37%
Shares change (YoY)	-4.23%
Shares held by insiders	4.95%
Shares held by institutions	81.7%
Shares outstanding	13.4M
Short % of float	3.25%
Short % of shares	2.74%
Short ratio	4.5 days

Deeper analysis on ANIK

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this ANIK report

Is a complete ANIK research report available?

No complete published report is available for Anika Therapeutics, Inc. (ANIK) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Anika Therapeutics, Inc. (ANIK)

Price

Financial snapshot

Fair-value bridge

Latest news · ANIK

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All ANIK indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on ANIK

Frequently asked questions